Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab today. The company’s shares closed yesterday at $32.75.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Goonewardene is an analyst with an average return of -6.6% and a 39.77% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Genmab, and Arcus Biosciences.
In addition to Truist Financial, Genmab also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued today. However, on September 30, TD Cowen maintained a Hold rating on Genmab (NASDAQ: GMAB).
The company has a one-year high of $33.63 and a one-year low of $17.24. Currently, Genmab has an average volume of 1.66M.
Read More on GMAB:
Disclaimer & DisclosureReport an Issue
- Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
- Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
- Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
- Genmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
- Genmab price target raised to $49 from $46 at Truist
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)